Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
22 participants
OBSERVATIONAL
2024-10-22
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comprehensive Segmental Revision System
NCT03270982
A Post-Market Clinical Evaluation of the ReUnion Reversible Fracture (RFX) System
NCT04089371
Perform Humeral System Study
NCT05067543
Clinical Evaluation of the Integra® Titan™ Modular Shoulder System Generation 2.5 for Primary Shoulder Joint Replacement
NCT03250767
Rejuvenate Modular Outcomes Study
NCT01257568
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objective is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications, and adverse events. Relation of the events to the implant and/or procedure should be specified.
The study will include one site. There will be a maximum of 103 patients enrolled in the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Comprehensive Regenerex Tissue Attachment Augments
Regenerex Tissue Attachment Augments were used in combination with the Comprehensive Segmental Revision system
Regenerex Tissue Attachment Augments
Patient will have been previously implanted with Regenerex Tissue Attachment Augments in combination with the Comprehensive Segmental Revision System
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Regenerex Tissue Attachment Augments
Patient will have been previously implanted with Regenerex Tissue Attachment Augments in combination with the Comprehensive Segmental Revision System
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient must be willing and able to follow directions.
* The Comprehensive Segmental Revision System was used in cases of:
1. Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.
2. Revision where other devices or treatments have failed.
3. Correction of functional deformity.
4. Oncology applications including bone loss due to tumor resection.
* Proximal or total humeral replacement, for: Treatment of acute or chronic fractures with humeral head (shoulder) involvement, which are unmanageable using other treatment methods.
* Distal or total humeral replacement for: Treatment of acute or chronic fractures with humeral epicondyle (elbow) involvement, which are unmanageable using other treatment methods.
* Biomet Comprehensive Segmental Revision System was used in a reverse application in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff for proximal humeral replacement. The patient must be anatomically and structurally suited to receive the implants and a functional deltoid muscle is necessary.
* The Comprehensive Segmental Revision System was used with bone cement in distal humeral and total humeral applications.
* Regenerex Tissue Attachment Augments were used in combination with the Comprehensive Segmental Revision System
Exclusion Criteria
* Infection
* Sepsis
* Osteomyelitis
* Patient is a prisoner
* Patient is a current alcohol or drug abuser
* Patient has a psychiatric illness or cognitive deficit that will not allow for proper informed consent
* Patient is unwilling to consent
* Relative contraindications:
* Uncooperative patient or patient with neurologic disorders who is incapable of following directions
* Osteoporosis
* Metabolic disorders which may impair bone formation
* Osteomalacia
* Distant foci of infections which may spread to the implant site
* Vascular insufficiency, muscular atrophy, or neuromuscular disease
* The Comprehensive Segmental Revision System was used in a reverse shoulder application in patients receiving radiation therapy
* The Comprehensive Segmental Revision System was used without bone cement in distal humeral and total humeral applications.
* Regenerex Tissue Attachment Augments weren't used during the patient's surgery
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zimmer Biomet
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Erin Osborn
Role: STUDY_DIRECTOR
Zimmer Biomet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Toman Orthopedics and Sports Med
Boca Raton, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMU2024-12E
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.